Cel­gene can breathe a sigh of re­lief as FDA ac­cepts once-spurned ozan­i­mod ap­pli­ca­tion — set­ting a tar­get date on a block­buster de­ci­sion

For most ma­jor bio­phar­mas, hav­ing your NDA ac­cept­ed for re­view is a non-event. At Cel­gene and Bris­tol-My­ers Squibb this morn­ing, it’s cause for cel­e­bra­tion.

The big biotech re­port­ed that both the FDA as well as the EMA have ac­cept­ed their ap­pli­ca­tion for ozan­i­mod, an ex­per­i­men­tal ther­a­py for mul­ti­ple scle­ro­sis. That’s by no means a guar­an­tee of ap­proval, but it does set the clock tick­ing on a ma­jor reg­u­la­to­ry de­ci­sion that is cen­tral to the suc­cess of the $74 bil­lion Cel­gene buy­out by Bris­tol-My­ers Squibb.

The PDU­FA date on this one now sits with a March 25, 2020 dead­line for the key reg­u­la­to­ry de­ci­sion in the US. The EMA’s an­swer will come in the first half of next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER